Other substances

Z-FA-FMK

A cystein protease inhibitor.

Phase of research

Potential treatment - pre-clinical evidence

How it helps

Antiviral

Drug status

Experimental

2
 Supporting references
0
 Contradictory references
2
 AI-suggested references
0
 Clinical trials

General information

Z-FA-FMK is an irreversible inhibitor of cysteine proteases such as cathepsin B. It was shown tu be a potent immunosuppressor (Lawrence et al., 2006).

Z-FA-FMK on PubChem
Z-FA-FMK on Wikipedia


Synonyms

benzyloxycarbonyl-phenyl-alanyl-fluoromethylketone; benzyloxycarbonyl-phenyl-alanyl-fluoromethylketone; Z-Phe-ala-CH2F

 

Structure image - Z-FA-FMK

CC(C(=O)CF)NC(=O)C(CC1=CC=CC=C1)NC(=O)OCC2=CC=CC=C2

Supporting references

Link Tested on Impact factor Notes Publication date
Morphological Cell Profiling of SARS-CoV-2 Infection Identifies Drug Repurposing Candidates for COVID-19
Preprint 		Huh7 cells May/27/2020
Development of a Cell-Based Luciferase Complementation Assay for Identification of SARS-CoV-2 3CLpro Inhibitors
3CLpro Small molecule Enzyme assay In vitro 		in vitro enzyme assay 3.82

The compound inhibited the SARS-CoV-2 3C-like protease in vitro with EC50 of 26.3 μM and CC50 of >100 μM.

 Jan/24/2021

AI-suggested references

Link Publication date
Potential Drug Discovery for COVID-19 Treatment Targeting Cathepsin L Using a Deep Learning-Based Strategy.
May/17/2022
Identification of SARS-CoV-2 3CL Protease Inhibitors by a Quantitative High-Throughput Screening.
Sep/04/2020
Export (.csv)